跳至主要内容
临床试验/NL-OMON27491
NL-OMON27491尚未招募不适用

A randomized multi-center trial of elective revascularization with EPC capturing stenting versus bare metal stenting in patients with de novo coronary lesions with a low risk of coronary restenosis: The Genous™ EPC capturing stent versus a bare metal stent

Investigator initiated study, AMC-UvA0 个研究点目标入组 1,260 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Clinically stable patients undergoing a PCI for a coronary artery lesion with a low risk of restenosis are candidates for entry into this study.
  • A target lesion is considered to be at a low risk of restenosis if all of the following apply:
  • 1. A de novo lesion located in a native epicardial vessel with a Reference Vessel Diameter (RVD) greater than 2.8 mm by visual estimation;
  • 2. A de novo lesion with a length of smaller than 20 mm by visual estimation;
  • 3. A de novo lesion with a TIMI flow equal to or greater than 1;
  • 4. The patient does not have diabetes mellitus

排除标准

  • 1. Younger than 18 years of age;
  • 2. A target lesion located in the left main coronary artery;
  • 3. A chronic, totally occluded (CTO) target lesion;
  • 4. A target lesion with involvement of a side branch, which is equal to or greater than 2.0 mm in diameter by visual estimation;
  • 5. A restenotic target lesion;
  • 6. A target lesion in an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft;
  • 7. A target lesion(s) with an indication for treatment with a drug-eluting stent (DES).
  • 8. Urgent need for revascularization;
  • 9. ST Elevation Myocardial Infarction (STEMI) within the past six weeks;
  • 10. Ventricular tachyarrhythmias within the past week;
  • 11. A diabetic patient ;
  • 12. Known renal insufficiency (e.g. serum creatinin level of more than 200 ìgram/L);
  • 13. Platelet count of less than 100,000 cells/ mm3 or more than 700,000 cells/ mm3, a WBC of less than 3,000 cells/ mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis);
  • 14. History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days of randomization;
  • 15. History of a hemorrhagic stroke at any time, or stroke or transient ischemic accident (TIA) of any etiology within 30 days of randomization;
  • 16. Previous or scheduled chemotherapy or radiotherapy within 30 days prior or after the procedure;
  • 17. On immune-suppression therapy or with known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
  • 18. Severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure over 100 mmHg, after treatment)
  • 19. Contraindication for treatment with the Genous™ EPC capturing stent, such as previous administration of murine therapeutic antibodies and exhibition of sensitization through the production of Human Anti-Murine Antibodies (HAMA).
  • 20. Known hypersensitivity or contraindication to aspirin, heparin or clopidogrel;
  • 21. Elective surgery, planned within the first 6 months after the procedure that requires discontinuing either aspirin or clopidogrel;
  • 22. Previous heart transplant or any other organ transplant;
  • 23. Previous participation in this study;
  • 24. Circumstances that prevent follow-up (no permanent home or address, transient, etc.);
  • 25. Women who are pregnant or who are of childbearing potential who do not use adequate contraception.

研究者

发起方
Investigator initiated study, AMC-UvA

相似试验